The study, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna, aims to elucidate the role of gut microbiota in influencing clinical outcomes in both pediatric and adult patients undergoing HCT and CAR-T therapy. Given the increasing recognition of microbiota's impact on treatment efficacy and safety, the findings could lead to the development of microbiota-informed risk stratification tools and personalized therapeutic strategies. This research may enhance patient outcomes and reduce healthcare costs associated with complications from these therapies. The market for microbiome-related interventions is expanding, with potential applications in antibiotic stewardship and microbiota-modulating therapies. Companies focusing on microbiome research and therapies may find strategic partnerships or investment opportunities arising from this study's outcomes.